Business Context and Reporting Period
PharmaCyte Biotech, Inc. (PMCB) filed this Form 8-K on August 9, 2021, to report the entry into a material definitive agreement. The company is incorporated in Nevada and trades on the Nasdaq Capital Market.
Key Financial Metrics and Transaction Details
This filing details a public offering rather than historical financial performance. Key transaction metrics include:
- Gross Proceeds: Approximately $15 million expected before underwriting discounts and expenses.
- Offering Price: $4.25 per share of common stock and accompanying warrant.
- Securities Issued:
- 2,630,385 shares of common stock.
- 899,027 pre-funded warrants (exercise price $0.001).
- 3,529,412 common warrants (exercise price $4.25, 5-year term).
- Over-Allotment Option: Underwriter granted a 30-day option to purchase up to 529,411 additional shares/warrants.
- Underwriting Costs: 7.5% underwriting discount plus 1% management fee.
- Underwriter Warrants: Warrants to purchase 7.5% of the shares sold in the offering issued to the underwriter.
The filing does not provide current revenue, profit, cash flow, or debt figures.
Material Changes and Outlook
The primary material change is the execution of the underwriting agreement with H.C. Wainwright & Co., LLC. The closing of the public offering is expected on August 12, 2021, subject to customary conditions. The company has agreed to a 90-day lock-up period for executive officers and directors regarding the sale of common stock or convertible securities.
Risks and Contingencies
- Closing Conditions: The transaction is subject to customary closing conditions; failure to meet these could delay or cancel the offering.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the closing and over-allotment option which are subject to risks and uncertainties.
- Variable Rate Transactions: The company agreed not to effect any issuance involving a Variable Rate Transaction for one year.
Investor Verification Checklist
- Verify the actual closing date and final gross proceeds received on or after August 12, 2021.
- Confirm the extent to which the underwriter exercised the 30-day over-allotment option.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific representations and warranties.
- Check subsequent filings for the impact of the 90-day lock-up period on insider trading activity.
- Monitor the company's cash position post-closing to assess liquidity improvements.